Diabetes, Obesity & Metabolism最新文献

{"title":"Trends in GLP-1 Receptor Agonist Prescribing Without Documented Indications.","authors":"Chungsoo Kim, Kyungseon Choi, Harlan M Krumholz, Yuan Lu","doi":"10.1111/dom.71153","DOIUrl":"10.1111/dom.71153","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10853-10856"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148667784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to 'Association of Cardiovascular-Kidney-Syndrome and Brain Macrostructure and Microstructure Injury: A Prospective Cohort Study'.","authors":"","doi":"10.1111/dom.71081","DOIUrl":"10.1111/dom.71081","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10917-10920"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthetic Versus Reference Semaglutide for Weight Management: Reporting Gaps and Clinical Claims.","authors":"Awadhesh Kumar Singh, Akriti Singh, Ritu Singh","doi":"10.1111/dom.71283","DOIUrl":"10.1111/dom.71283","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10899-10901"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148811472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Risk in Type 2 Diabetes With Substance Use Disorders: Questions of Exposure and Effect Modification.","authors":"Laurent Fauchier, Mickael Guglieri, Thibaud Genet","doi":"10.1111/dom.71288","DOIUrl":"10.1111/dom.71288","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10905-10906"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to 'Glucose Tolerance and Mortality Across 24 Cancer Types and Stages: A K-CURE Nationwide Registry Study'.","authors":"","doi":"10.1111/dom.71276","DOIUrl":"10.1111/dom.71276","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10923"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes.","authors":"Tik Muk, Tina Okdahl, Marietta Kokla, Tommi Suvitaival, Gurjeet Kaur, Ismo M Mattila, Simon M Kienle, Christian Buhl, Knud Yderstræde, Troels S Jensen, Peter Rossing, Flemming Pociot, Birgitte Brock, Cristina Legido-Quigley, Páll Karlsson, Christian S Hansen, Christina Brock, Joachim Størling, Karolina Sulek","doi":"10.1111/dom.71257","DOIUrl":"10.1111/dom.71257","url":null,"abstract":"<p><strong>Background: </strong>Distal symmetrical polyneuropathy (DSPN) is a common complication of type 1 diabetes (T1D), yet validated biomarkers for early detection or prognosis are lacking. Metabolic disturbances driven by chronic hyperglycemia and dyslipidemia contribute to DSPN development and progression.</p><p><strong>Methods: </strong>We used untargeted serum liquid chromatography-mass spectrometry lipidomics to identify DSPN biomarkers. The discovery cohort included 153 individuals with T1D (109 with and 44 without DSPN) and 50 non-diabetic controls. The independent validation cohort included 99 individuals with T1D with established DSPN status. Key lipids were identified using multivariate modelling, followed by ANCOVA and adjusted post hoc tests.</p><p><strong>Results: </strong>A total of 543 lipid species were identified in the discovery cohort. Among these, 14 lipids were associated with DSPN. Of which, 6 lipids, namely Cer(d42:1), PC(36:4), LPC(16:0), LPE(18:1), PE(36:2), and PE(O-40:5) or PE(P-40:4), showed a clear pattern among non-diabetic individuals, people affected by T1D with and without DSPN. In the validation cohort, 3 of the 6 initially identified lipids showed the same directional changes as in the discovery cohort. A logistic regression model combining the six lipid biomarkers with HbA1c, diastolic blood pressure, and age achieved AUCs of 0.83 (95% CI, 0.76-0.91) in the discovery cohort and 0.81 (95% CI, 0.73-0.90) in the validation cohort for detecting DSPN in T1D. AUC improvement was not significant by DeLong's test in either cohort (p = 0.086 and 0.089) but was significant when combined using Fisher's method (χ² = 9.7, p = 0.045). Additionally, 22 lipid species differed significantly between painful and painless DSPN.</p><p><strong>Conclusions: </strong>We identified a reproducible lipidomic signature discriminating DSPN in type 1 diabetes. Painful DSPN was characterized by reduced unsaturated PC/PE and increased sphingolipids, offering new insight into disease pathophysiology.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10670-10682"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Metabolically Healthy Is Not Low Risk: BMI Thresholds for Incident Diabetes in East Asian Adults.","authors":"Yibo Li, Xinyi Liu, Lijing Shang, Yuhao Wang, Zhongyin Chen, Yuehang Yang, Linfeng He","doi":"10.1111/dom.71235","DOIUrl":"10.1111/dom.71235","url":null,"abstract":"<p><strong>Aims: </strong>To determine whether metabolic health attenuates body mass index (BMI)-related risk of diabetes in East Asian adults and to identify BMI thresholds at which risk increases among metabolically healthy individuals.</p><p><strong>Materials and methods: </strong>We analysed 125 843 adults from two longitudinal cohorts, including 113 354 Chinese and 12 489 Japanese participants. Metabolic health was stringently defined as the absence of elevated blood pressure, dyslipidaemia and impaired fasting glucose. Participants were categorised by BMI and metabolic health status. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for incident diabetes, using metabolically healthy normal weight (MHNW) as the reference. Restricted cubic splines assessed non-linear BMI-diabetes associations by metabolic health status.</p><p><strong>Results: </strong>During 352 036 Chinese and 89 483 Japanese person-years, 1483 and 312 participants, respectively, developed diabetes. In the primary model adjusted for age, gender, smoking, and drinking, compared with MHNW, metabolically healthy overweight was associated with incident diabetes in Chinese (HR: 2.33, 95% CI: 1.63-3.33) and Japanese participants (HR: 3.32, 95% CI: 1.50-7.35). Metabolically healthy obesity (MHO) was also associated with a higher risk (Chinese: HR: 12.40, 95% CI: 6.77-22.68; Japanese: HR: 27.89, 95% CI: 8.42-92.41). The reported change points were 22.2 kg/m² in Chinese and 21.8 kg/m² in Japanese metabolically healthy participants.</p><p><strong>Conclusions: </strong>Metabolic health did not eliminate BMI-related diabetes risk in East Asian adults. Diabetes risk increased at BMI levels below conventional overweight thresholds, supporting joint assessment of BMI and metabolic health for diabetes risk stratification.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10227-10235"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Butyrate Reduces Progression of Kidney Damage in an L-NAME-Induced Diabetic Kidney Disease Mouse Model.","authors":"Maria Novella Nicese, Angela Koudijs, Reshma Lalai, Cristina Avramut, Rico J E Derks, Elena Sánchez-López, Martin Giera, Amanda C M Pronk, Artemiy Kovynev, Sander Kooijman, Patrick C N Rensen, Roel Bijkerk, Bernard M van den Berg, Joris I Rotmans","doi":"10.1111/dom.71245","DOIUrl":"10.1111/dom.71245","url":null,"abstract":"<p><strong>Aims: </strong>Diabetic kidney disease (DKD) is one of the main causes of kidney failure worldwide. Interestingly, patients affected by DKD are characterised by a low abundance of gut bacteria producing short fatty acids including butyrate, which is suggested to play a role in the decline of renal function. Consequently, we aimed to test the effects of oral butyrate supplementation on kidney health in mice affected by DKD.</p><p><strong>Material and methods: </strong>To this end, we treated diabetic BKS db/db mice (C57BLKS/J Lepr ^db ) via drinking water with the eNOS inhibitor N(ω)-nitro-L-arginine methyl ester (L-NAME), which accelerates the progression of DKD. Simultaneously, mice were fed low-fat chow with or without 5% butyrate.</p><p><strong>Results: </strong>Oral butyrate supplementation reduced mesangial expansion, glomerular enlargement and medullary fibrosis in kidney biopsies of the mice. These protective effects correlated with an increased abundance of Akkermansiaceae in the gut. In mice treated with butyrate, the abundance of Akkermansiaceae positively correlated with glomerular filtration rate (GFR) and plasma concentration of indole-3-methyl acetate and indole-3-acetaldehyde, key metabolites associated with many beneficial cardiovascular effects.</p><p><strong>Conclusions: </strong>In conclusion, oral butyrate supplementation in mice with DKD improves kidney morphology, accompanied by an increased abundance of Akkermansiaceae in the gut. Future studies, such as transplantation of Akkermansia, should reveal whether this relationship is causal and translate into improved kidney function in DKD.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10278-10291"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten-Year Cost-Effectiveness of the Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) Relative to Usual Care in Hong Kong Public Primary Care: A Population-Based Cohort Study.","authors":"Eric Ho Man Tang, Ivy Lynn Mak, Emily Tsui Yee Tse, Esther Yee Tak Yu, Julie Yun Chen, Weng Yee Chin, David Vai Kiong Chao, Wendy Wing Sze Tsui, Tony King Hang Ha, Carlos King Ho Wong, Cindy Lo Kuen Lam, Eric Yuk Fai Wan","doi":"10.1111/dom.71242","DOIUrl":"10.1111/dom.71242","url":null,"abstract":"<p><strong>Aims: </strong>The Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) is a multidisciplinary, protocol-driven, risk-stratified care model integrated into public primary care in Hong Kong for patients with type 2 diabetes mellitus (T2DM). This study evaluated the real-world 10-year cost-effectiveness of RAMP-DM from the public healthcare provider perspective.</p><p><strong>Materials and methods: </strong>Programme costs from 2009 to 2019 were estimated using costing questionnaires and reported in 2019 US dollars. Direct medical costs were compared between patients enrolled in RAMP-DM and a propensity-score matched cohort receiving usual care only. Effectiveness was based on previously published 10-year estimates of absolute risk reduction in complications and all-cause mortality. The primary outcome was the incremental total direct medical cost per diabetes-related complication avoided over 10 years. Secondary outcomes included incremental cost per all-cause mortality avoided and programme cost per complication avoided. Sensitivity analyses examined the effects of parameter uncertainty and discounting.</p><p><strong>Results: </strong>A total of 36 746 patients (18 373 in each group) were included. RAMP-DM was associated with absolute risk reductions of 12.1% for any complications and 16.2% for all-cause mortality. Accounting for the programme cost of US$329 per participant, total undiscounted direct medical costs over 10 years was US$10 543 lower per person among RAMP-DM participants (RAMP-DM: $23 430; usual care: US$33 973). RAMP-DM was a cost-saving strategy relative to usual care.</p><p><strong>Conclusions: </strong>RAMP-DM was associated with better 10-year clinical outcomes and lower direct medical costs. These findings support the economic value of structured multidisciplinary diabetes management programmes in publicly funded primary care settings, although residual confounding and uncertainty in cost estimates should be considered.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10379-10389"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148807926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-Dimensional Barriers for Work Productivity and Possible Solutions to Overcome Presenteeism in Young-Onset Diabetes: A Mixed-Methods Study.","authors":"Kelly T C Wong, Jason D C Yin, Sunny C S Chan, Nga Sze Wong, Chun-Kwan O, Yiming Dai, Yuzheng Zhang, Marques S N Ng, Risa Ozaki, Ronald C W Ma, Alice P S Kong, Andrea O Y Luk, Elaine Y K Chow, Juliana C N Chan, Juliana N M Lui","doi":"10.1111/dom.71158","DOIUrl":"10.1111/dom.71158","url":null,"abstract":"<p><strong>Aims: </strong>Young-onset non-type 1 diabetes (YOD, age-at-diagnosis ≤ 40) is associated with poor physical and mental health, presenteeism and productivity loss. We examined patient-perceived barriers to work productivity and key enablers to reduce presenteeism.</p><p><strong>Materials and methods: </strong>In this mixed-methods study, we utilized validated questionnaires to measure presenteeism (World Health Organization Health and Performance Questionnaire); self-care activities (Summary of Diabetes Self-Care Activities; Compliance Questionnaire for Medication); health-related quality of life (HRQoL, EQ-5D-3L) and psychological distress (Depression Anxiety Stress Scale; Chinese Diabetes Distress Scale) among participants with YOD in the Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes-Randomised Controlled Trial (PRISM-RCT). We conducted four semi-structured focus group discussions (FGDs) for inductive thematic analysis.</p><p><strong>Results: </strong>Employees with YOD (n = 465, mean age: 43.4 ± 6.4 years, disease duration: 10.9 ± 6.0 years, 59.8% male) had better cardiometabolic, psychological and HRQoL profiles than non-employees (n = 103). Among the employees, 67.4% had at least one sickness presenteeism episode in the preceding year, with a mean presenteeism score of 7.1 ± 1.6 (out of 10). Increased presenteeism was independently associated with diabetes-related emotional burden (β = -0.08, p = 0.029) and suboptimal HRQoL (β = 3.30, p = 0.041). [Correction added on 11 September 2026, after first online publication: In the preceding sentence, the beta and p values have been corrected.] Participants of FGDs (n = 16) reported distress contributors related to inter-personal (psychological/physical status, family collectivism), work (schedules/types, absence justification, colleagues' attitudes) and societal factors (relationships with providers, out-of-pocket payment, stigmatisation). Enablers included public awareness, early diagnosis (genetic testing for offspring, regular health-check), peer support, treatment choices autonomy and insurance coverage.</p><p><strong>Conclusion: </strong>In YOD, presenteeism is associated with interpersonal, work and societal factors accompanied by psychological distress, suboptimal diabetes care, self-management challenges, calling for holistic assessment and person-centred management.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10540-10554"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148823706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}